Search
Article

ATHENA Trial

Shaping our Understanding of the Role of High-Risk HPV Testing in Cervical Cancer Screening

The ATHENA HPV trial was a large, prospective clinical trial evaluating the performance of the cobas® HPV test in three relevant populations*: women with ASC-US (Atypical Squamous Cells of Undetermined Significance) cervical cytology (≥21 years), women with normal cervical cytology (≥30 years), and an overall screening population (25+ years) to explore HPV as a first-line test (longitudinal 3 year trial).1, 2, 3, 4 ATHENA, with over 47,000 women enrolled, also set out to evaluate the medical value of testing for pooled hrHPV DNA as well as genotypes HPV 16 and HPV 18 individually.

*Women <25 years (n=4,183) with normal cytology exited the trial.

Related portfolios

ATHENA Key Findings:

 

The cobas® HPV test was clinically validated in ATHENA, the first screening trial for registration that evaluated simultaneous real-time genotyping of 12 pooled hrHPV genotypes plus HPV 16 and HPV 18 individually. The ATHENA trial evaluated the performance of the cobas® HPV test in multiple clinical situations, including primary screening, ASC-US triage and co-testing (HPV and Pap cytology).

ATHENA not only validated the cobas® HPV test as comparable to the current standard of pooled hrHPV testing within the ASC-US population, but the trial also quantified risk of precancer and cervical cancer in HPV 16+ and/or HPV 18+ women who had ASC-US or who had normal cytology.

The ATHENA trial demonstrated that one in four women who are HPV 16 positive will have cervical disease within three years and that nearly 1 in 7 women with normal Pap cytology who were HPV 16 positive actually had high-grade cervical disease that was missed by cytology.

In addition, results from the ATHENA trial included a comparison of a cobas® HPV test screening strategy to alternative strategies using Pap cytology and HPV testing. The comparison showed that a strategy leveraging the ability of the cobas® HPV test to identify women testing positive for HPV 16 or 18, and using cervical cytology (Pap) as a triage, follow-up test, would allow clinicians to detect more disease without referring a significantly greater number of women to unnecessary follow-up. In 2014, based on ATHENA trial data, the U.S. FDA approved for the first time the use of the Roche cobas® HPV test for first-line primary screening in women 25 and older.

 

ATHENA Principal Publications

 

  • High-risk human papillornavirus testing in women with ASC-US cytology: results from the ATHENA HPV study (Stoler MH, et al. Arn J Clin Pathol. 2011 ;135(3):468-75)
  • Evaluation of HPV-16 and HPV-18 genotyping for the triage of women with high­risk HPV+ cytology-negative results (Wright TC, Jr., et al. Arn J Clin Pathol. 2011; 136(4):578-86)
  • Performance of carcinogenic human papillornavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older a subanalysis of the ATHENA study (Castle PE, Stoler MH, Wright TC Jr, et al. Lancet On col 2011; 12:880-890)
  • The ATHENA human papillomavirus study: design, methods, and baseline results (Wright TC Jr, Stoler MH, Behrens CM, Apple R, Derion T, Wright TL Arn J Obstet Gynecol 2011; 1 :e 1-e 11)
  • Comparison of cervical cancer screening strategies incorporating different combinations of cytology, HPV testing, and genotyping for HPV 16/18 results from the ATHENA HPV study (Cox JT, Castle PE, Behrens CM, et al. Arn J Obstet Gynecol 2012; 184:el-el 1)
  • Primary cervical cancer screening with human papillornavirus: end of study results from the ATHENA study using HPV as the first-line screening test (Wright TC, et al. Gynecol Oncol. 2015;136(2):189-97)
  • Triaging HPV-Positive Women with p16/Ki-67 Dual-stained Cytology Results from a Sub-study Nested into the ATHENA Trial, Wright et al, Gyn Oncology, January 2017 (online 2016)
cobas® HPV Test image

cobas® HPV

cobas® HPV Test: Delivering confidence with 3-in-1 HPV test results

cobas® HPV tests help identify a woman's risk for cervical disease. HPV DNA genotype screening is part of Roche's portfolio for cervical cancer prevention.

You might be interested in

...
    ...

    References

    1. Wright TC, Jr., et al. The ATHENA human papillomavirus study: design, methods, and baseline results. Am J Obstet Gynecol. 2012;206(1):46 e1- e11
    2. Stoler MH, et al. High-risk human papillomavirus testing in women with ASC-US cytology: results from the ATHENA HPV study. Am J Clin Pathol. 2011;135(3):468-75. (for ASC-US CYTOLOGY)
    3. Wright TC, Jr., et al. Evaluation of HPV-16 and HPV-18 genotyping for the triage of women with high-risk HPV+ cytology-negative results. Am J Clin Pathol. 2011;136(4):578-86. (FOR CO-TESTING)
    4. Wright TC, et al. Primary cervical cancer screening with human papillomavirus: end of study results from the ATHENA study using HPV as the first-line screening test. Gynecol Oncol. 2015;136(2):189-97. (FOR PRIMARY SCREENING)